Abstract
Efficacy, tolerability, quality of life and spasticity in outpatients with remitting multiple sclerosis (RMS) treated with glatiramer acetate (GA) - Results of an observational study
Highlights
Spasticity is a shared feature in many neurological conditions including multiple sclerosis (MS), cerebral ischemia and spinal cord injury
A representative sample of remitting multiple sclerosis (RMS) patients was assessed during daily practice conditions
Results indicate the potential of immune modulating therapy to stabilize progression of disease measured by more conventional instruments as annualized relapse rate (ARR) and Expanded Disablity Status Scale (EDSS), and to keep stable the progression of spasticity symptoms as assessed by established and new scales
Summary
Spasticity is a shared feature in many neurological conditions including multiple sclerosis (MS), cerebral ischemia and spinal cord injury. The enormous heterogeneity GA consists of about 1029 different amino acids This is thought to trigger a shift of derailed immune system in MS patients resulting in therapeutic effects shown in non-progressive stages of the disease, mostly demonstrated as reduction of annualized relapse rate in controlled clinical trials or observational protocols. Former clinical investigations showed spasticity improvements in RRMS patients switched from interferon- β to GA [8]. The aim of this project was to observe spasticity and its possible improvement using the new standardized multiple sclerosis spasticity scale (MSSS-88) to compare with other instruments for assessment of burden of disease in patients treated with Glatiramer acetate (Copaxone®), an approved disease-modifying agent consisting in millions of different polypeptides and amino acids
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
